Welcome to our dedicated page for LB Pharmaceuticals SEC filings (Ticker: LBRX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
LB Pharmaceuticals Inc filings document a Nasdaq-listed Delaware biopharmaceutical company developing LB-102 for neuropsychiatric diseases. Registration statements describe securities offerings and capital-structure terms for common stock, while current reports record operating and financial results, clinical-development updates, material agreements and governance events.
Proxy materials cover annual meeting matters, director elections and auditor ratification. The filing record also includes disclosures on executive and board changes, compensatory arrangements, inducement equity awards, lease agreements and shareholder voting matters tied to a late-stage drug development company.
LB Pharmaceuticals Inc filed a prospectus supplement dated June 10, 2026 that incorporates a Form 8-K reporting the resignation of Chief Medical Officer Anna Eramo, M.D., effective June 15, 2026, and her transition to an adviser and consultant through September 15, 2026. The supplement describes a Separation and Consulting Agreement providing consulting services during a three-month Consulting Period, continuation of option vesting per company plans, reimbursement of COBRA healthcare premiums for up to 12 months, payment of base salary on a monthly basis through June 15, 2027, a prorated 100% target annual bonus for 2026, and acceleration such that 66,143 unvested option shares will vest and become exercisable on September 15, 2026. The company states Dr. Eramo’s departure is for personal reasons, is not related to clinical program operations or practices, and is not expected to have a material impact on clinical development activities or disclosed clinical milestones. The prospectus supplement updates the Registration Statement on Form S-1 (Registration No. 333-294900) and should be read with the Prospectus.
LB Pharmaceuticals Inc. announced that Chief Medical Officer Anna Eramo, M.D. resigned her officer role effective June 15, 2026, for personal reasons and will transition to an advisor role. She will continue providing full-time consulting services through September 15, 2026 while the company searches for a replacement.
The company states that her departure is not related to its clinical program operations or practices and does not expect a material impact on clinical development activities or previously disclosed milestones. Existing clinical development and operations teams will keep overseeing ongoing trials.
Under a Separation and Consulting Agreement dated June 8, 2026, if Dr. Eramo serves through the consulting period and complies with her obligations, she will receive her current base salary paid monthly until June 15, 2027, a prorated 2026 target bonus, and accelerated vesting of 66,143 unvested option shares on September 15, 2026. Her other options continue vesting under existing equity plans, and the company will reimburse COBRA healthcare premiums for up to 12 months, subject to earlier termination conditions.
LB Pharmaceuticals Inc filed a prospectus supplement to its Registration Statement on Form S-1 to update the Prospectus with information from a Current Report on June 9, 2026.
The company held its 2026 Annual Meeting on June 3, 2026. Stockholders elected three Class I directors for three-year terms: Robert A. Lenz, M.D., Ph.D. (20,059,577 votes for), Rebecca Luse (18,530,680 votes for), and Ran Nussbaum (18,748,511 votes for). Stockholders also ratified the appointment of BDO USA, P.C. as the independent registered public accounting firm with 23,275,974 votes for.
LB Pharmaceuticals Inc. reported the results of its 2026 Annual Meeting of Stockholders. Three Class I directors — Robert A. Lenz, M.D., Ph.D., Rebecca Luse, and Ran Nussbaum — were elected to three-year terms ending at the 2029 annual meeting.
Stockholders also ratified the appointment of BDO USA, P.C. as the independent registered public accounting firm for the fiscal year ending December 31, 2026, with a strong majority of votes cast in favor and minimal opposition or abstentions.
LB Pharmaceuticals director Robert R. Ruffolo received a stock option grant covering 10,000 shares of common stock. The options have an exercise price of $27.95 per share and expire on June 2, 2036.
According to the terms, 100% of the shares underlying the option vest on the earlier of June 3, 2027 or the date of the company’s next annual meeting of stockholders, as long as he remains in continuous service through the vesting date. After this grant, Ruffolo holds 10,000 stock options directly.
LB PHARMACEUTICALS INC director Ran Nussbaum received a new stock option grant. He was awarded options for 10,000 shares of common stock at an exercise price of $27.95 per share, expiring on June 2, 2036.
All 10,000 underlying shares vest on the earlier of June 3, 2027 or the company’s next annual meeting of stockholders, provided he remains in continuous service through that date. Following this compensation grant, he holds 10,000 stock options directly, with no open‑market buying or selling reported in this filing.
LB Pharmaceuticals Inc director Rebecca Luse received a grant of stock options covering 10,000 shares of common stock. The options have an exercise price of $27.95 per share and expire on June 2, 2036. All underlying shares vest on the earlier of June 3, 2027 or the company’s next annual stockholder meeting, as long as she remains in continuous service.
LB Pharmaceuticals director Robert A. Lenz received a grant of stock options covering 12,500 shares of common stock. The options carry an exercise price of $27.95 per share and expire on June 2, 2036, functioning as equity-based compensation rather than an open-market trade.
Footnotes explain that 2,500 of these options represent a prorated annual grant for a prior year under the company’s non-employee director compensation policy. All 12,500 underlying shares vest 100% on the earlier of June 3, 2027 or the company’s next annual meeting of stockholders, contingent on Mr. Lenz’s continuous service.
LB Pharmaceuticals director Rekha Hemrajani received a new stock option grant tied to the company’s common stock. The award covers 10,000 shares with an exercise price of $27.95 per share and expires on June 2, 2036.
These options were granted as compensation and not purchased on the open market. All 10,000 underlying shares vest on the earlier of June 3, 2027 or the company’s next annual meeting of stockholders, if she remains in continuous service through that date. Following this grant, she holds 10,000 stock options directly.